EU/3/02/111

Table of contents

About

On 11 September 2002, orphan designation (EU/3/02/111) was granted by the European Commission to Ethicare GmbH, Germany, for benzoic acid, sodium salt for the treatment of non-ketotic hyperglycinaemia.

The sponsorship was transferred to Lucane Pharma SA, France, in November 2016.

Key facts

Active substance
Benzoic acid, sodium salt
Disease / condition
Treatment of non-ketotic hyperglycinaemia
Date of first decision
11/09/2002
Outcome
Positive
EU designation number
EU/3/02/111

Sponsor's contact details

Lucane Pharma SA
172 rue de Charonne
75011 Paris
France
Tel. + 33 1 53 868 750
E-mail: info@lucanepharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating